Non-peptide ligands for peptide receptors

doi:10.1016/0165-6147(89)90026-6

Trends in Pharmacological Sciences

Volume 10, Issue 7, July 1989, Pages 270-274

https://doi.org/10.1016/0165-6147(89)90026-6 Get rights and content

Abstract

Considerable progress has been made in synthesizing peptide analogs with improved stability for probing function of peptide-receptor systems. However, since peptide ligands are usually unsuitable for development as potent orally active long-duration therapeutic agents, considerable research effort is being directed to the development of non-peptidal ligands.Roger Freidinger compares the lead compounds that have now been described in the opioid, CCK-gastrin and angiotensin II fields, and discusses the progress that has been made in other receptor fields. Most of the successes have been achieved through screening natural sources and synthetic collections. Rational design based on the natural peptide ligand has been more difficult, although ACE inhibitors have been effectively developed from a nonapeptide lead.

References (29)

D.F. Veber et al.
Trends Neurosci.
(1985)
D. Regoli
Trends Pharmacol. Sci.
(1985)
R. Quirion et al.
Neurosci. Biobehav. Rev.
(1985)
J.S. Morley
Trends Pharmacol. Sci.
(1980)
R.E. Chipkin et al.
Annu. Rep. Med. Chem.
(1988)
A.T. Chiu
Eur. J. Pharmacol.
(1988)
Y. Kondo et al.
Biochem. Biophys. Res. Commun.
(1988)
M. Kahn et al.
Tetrahedron Lett.
(1986)
L. Zhang et al.
Biochim. Biophys. Acta.
(1988)
D.T. Krieger
Science
(1983)

A.S. Dutta

Drugs Future

(1988)

T. Beveridge

Curr. Ther. Res.

(1981)

R.M. Freidinger

Med. Res. Rev.

(1989)

Cited by (70)

Therapeutic Potential of Integrin Antagonists
2012, Integrins: Molecular and Biological Responses to the Extracellular Matrix
This chapter discusses the therapeutic potential of integrin antagonists. As the physiological importance of integrins becomes better defined so do strategies to perturb their function for therapeutic benefit. There is currently great interest and excitement concerning adhesion molecules as drug targets. This is evident by increased research activities at nearly all major pharmaceutical houses and the spawning of numerous biotech companies focused on adhesion molecules. Research activities are targeted toward inflammation, infectious disease, cancer, and hemostasis. In most of these therapeutic areas, the most useful reagents are neutralizing monoclonal antibodies. The chapter discusses the most advanced area of drug discovery, the antithrombotic antagonists of the integrin αII/β3. In this arena, selective low molecular weight compounds have entered clinical trials. The chapter discusses work from the laboratories to illustrate progress in the development of platelet fibrinogen receptor antagonists. Italso describes an extension of research to the field of skeletal physiology and the potential treatment of osteoporosis.
Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor
2012, Journal of Biological Chemistry
Citation Excerpt :
In contrast, at the CCK2R, the carboxyl-terminal end of the peptide may be sited closer to the helical bundle (12, 20, 21). Selective, small molecule ligands have been developed for both CCK1R and CCK2R (22, 23). It is now clear, based on limited receptor mutagenesis, photoaffinity labeling, and pharmacological manipulations, that these ligands bind to an allosteric site within the intramembranous helical bundle that is distinct from the orthosteric CCK peptide-binding site of the CCK1R (24–27).
Allosteric binding pockets in peptide-binding G protein-coupled receptors create opportunities for the development of small molecule drugs with substantial benefits over orthosteric ligands. To gain insights into molecular determinants for this pocket within type 1 and 2 cholecystokinin receptors (CCK1R and CCK2R), we prepared a series of receptor constructs in which six distinct residues in TM2, -3, -6, and -7 were reversed. Two novel iodinated CCK1R- and CCK2R-selective 1,4-benzodiazepine antagonists, differing only in stereochemistry at C3, were used. When all six residues within CCK1R were mutated to corresponding CCK2R residues, benzodiazepine selectivity was reversed, yet peptide binding selectivity was unaffected. Detailed analysis, including observations of gain of function, demonstrated that residues 6.51, 6.52, and 7.39 were most important for binding the CCK1R-selective ligand, whereas residues 2.61 and 7.39 were most important for binding CCK2R-selective ligand, although the effect of substitution of residue 2.61 was likely indirect. Ligand-guided homology modeling was applied to wild type receptors and those reversing benzodiazepine binding selectivity. The models had high predictive power in enriching known receptor-selective ligands from related decoys, indicating a high degree of precision in pocket definition. The benzodiazepines docked in similar poses in both receptors, with C3 urea substituents pointing upward, whereas different stereochemistry at C3 directed the C5 phenyl rings and N1 methyl groups into opposite orientations. The geometry of the binding pockets and specific interactions predicted for ligand docking in these models provide a molecular framework for understanding ligand selectivity at these receptor subtypes. Furthermore, the strong predictive power of these models suggests their usefulness in the discovery of lead compounds and in drug development programs.
Bioavailability of insect neuropeptides: The PK/PBAN family as a case study
2009, Peptides
The ability of unmodified linear peptides to penetrate the insect cuticle and exert bioactivity (e.g., stimulation of sex pheromone biosynthesis) was tested by topical application onto Heliothis peltigera moths of four insect neuropeptides (Nps) of the pyrokinin (PK)/pheromone biosynthesis activating neuropeptide (PBAN) family: Helicoverpa zea PBAN (Hez-PBAN), Pseudaletia (Mythimna) separata pheromonotropin (PT), Leucophaea maderae PK (LPK) and Locusta migratoria myotropin (Lom-MT-II). The time kinetic of the peptides applied in double distilled water (DDW) or dimethylsulfoxide (DMSO) was tested and the activities of topically applied and injected peptides were compared. The results clearly indicated that all four peptides were highly potent but with differing activities in the two solvents: PBAN was most active in water, and PT in DMSO. The activity of PBAN in DDW lasted up to 8 h post-application and its activity in this solvent showed a faster onset and a longer persistence than in DMSO. LPK and MT differed less in their kinetics between the two solvents. Topically applied PBAN at 1 nmol exhibited an equivalent or even significantly higher potency than the injected peptide at several different times post-treatment. Similar results were obtained with topically applied and injected LPK. The present results add important information on the bioavailability of unmodified linear peptides in moths, clearly indicate that linear hydrophilic peptides can penetrate the cuticle by contact application in aqueous solutions and in organic solvents very efficiently, reach their target organ and activate it.
Skeletal diversity by allylation/RCM on Ugi four-component coupling reaction products
2006, Tetrahedron Letters
Here, we report a diversity-oriented synthetic approach toward skeletally diverse, cyclized peptidomimetics with diverse appendages. Starting from α-(N-acylamino)amides with various appendages, 12 to 16-membered lactams with defined olefin geometry were synthesized by a common synthetic sequence. We also synthesized the macrocycle in a liquid phase directed toward a construction of the peptidomimetics library.
β-Turn mimetic library synthesis: Scaffolds and applications
2001, Tetrahedron
Nonpeptidic ligands for peptide and protein receptors
1999, Current Opinion in Chemical Biology
The first potent nonpeptidic ligands for somatostatin, luteinizing hormone-releasing hormone, glucagon and bradykinin receptors have been reported. Nonpeptidic clinical candidates have been identified or are currently under study for substance P, bradykinin, endothelin, growth hormone secretagogue, angiotensin, vasopressin, motilin and cholecystokinin. Design, screening, combinatorial chemistry and classical medicinal chemistry all played important roles in these advances.

View all citing articles on Scopus

View full text

Trends in Pharmacological Sciences

Tips reviewsNon-peptide ligands for peptide receptors

Abstract

Trends Neurosci.

Trends Pharmacol. Sci.

Neurosci. Biobehav. Rev.

Trends Pharmacol. Sci.

Annu. Rep. Med. Chem.

Eur. J. Pharmacol.

Biochem. Biophys. Res. Commun.

Tetrahedron Lett.

Biochim. Biophys. Acta.

Science

Drugs Future

Curr. Ther. Res.

Med. Res. Rev.

Tips reviews
Non-peptide ligands for peptide receptors